Amneal Pharmaceuticals (AMRX) Q1 2025 earnings summary

Executive summary

• Q1 2025 net revenue reached $695.4 million, up 5.5% year-over-year, with all segments contributing and CREXONT® showing strong uptake and expanded coverage.

• Adjusted EBITDA rose 12% to $170 million, and adjusted diluted EPS increased 50% to $0.21.

• Net income was $24.6 million, reversing a net loss of $81.7 million in Q1 2024, reflecting improved profitability and absence of large legal charges.

• Growth was driven by diversified portfolio, new product launches, and strong execution in specialty, generics, and biosimilars.

• Strategic investments in U.S. manufacturing, innovation, and partnerships (notably in GLP-1s with Metsera) underpin long-term growth.

Financial highlights

• Net revenue: $695.4 million, up 5.5% year-over-year; adjusted EBITDA: $170 million, up 12%; adjusted EPS: $0.21, up 50%.

• Gross margin improved to 36.8% from 36.1% year-over-year; adjusted gross margin: 43.1%, up 120 basis points.

• Operating income: $100.3 million, compared to a loss of $10.7 million in Q1 2024.

• Operating cash flow for Q1 2025: $21.1 million; cash and equivalents at quarter-end: $59.2 million.

• Affordable medicines revenue: $415 million, up 6%; specialty: $108 million, up 3%; AvKARE: $172 million, up 6%.

Outlook and guidance

• Full-year 2025 guidance affirmed: net revenue $3.0–$3.1 billion (7–11% growth), adjusted EBITDA $650–$675 million (4–8% growth), adjusted EPS $0.65–$0.70 (12–21% growth).

• Operating cash flow projected at $255–$310 million; capital expenditures expected at $100–$120 million.

• CREXONT expected to meet or exceed $50 million in 2025 revenue; peak U.S. sales projected at $300–$500 million.

• Healthcare segment revenue expected to surpass $900 million by 2027.

• Management expects sufficient liquidity for the next 12 months, supported by cash, operations, and expanded credit facilities.